The November 28 PDUFA date is the next major binary catalyst. With Priority Review and no filing issues identified, approval odds are elevated. The Azurity partnership provides a credible commercial pathway and removes financing risk. Traders should position for approval upside into the PDUFA, but manage size given binary regulatory risk.
Price Chart
Executive Summary
PolyPid reported Q2 2026 results alongside a transformative corporate update: FDA accepted D-PLEX NDA with Priority Review (PDUFA Nov 28, 2026), and the company secured a $30M upfront from a U.S./Canada partnership with Azurity (up to $320M total milestones plus tiered royalties up to mid-twenties percent). Net loss narrowed to $7.8M ($0.35/share) from $10.0M ($0.78) YoY, with cash of $6.6M at quarter-end (excluding the $30M received post-quarter). The filing de-risks the approval timeline and eliminates near-term financing overhang, making this a pivotal catalyst event.
Key Facts
- FDA accepted D-PLEX NDA with Priority Review; PDUFA goal date November 28, 2026 (one quarter ahead of prior guidance).
- Exclusive U.S./Canada commercialization partnership with Azurity Pharmaceuticals; $30M in upfront and near-term milestones achieved post-NDA acceptance.
- Total potential milestone payments up to ~$320M plus tiered royalties from mid-teen to mid-twenties percentages on sales.
- Phase 3 SHIELD II trial met primary endpoint with 60% relative risk reduction in SSIs (p=0.0013).
- Q2 2026 net loss of $7.8M ($0.35/share) vs $10.0M ($0.78/share) in Q2 2025.
- Cash and cash equivalents of $6.6M at June 30, 2026; $30M from Azurity received post-quarter, extending runway into 2028.
- MAA submission to EMA on track for Q3 2026; potential U.S. commercial launch targeted for early 2027.
Financial Impact
$30M upfront and near-term milestones received; up to $320M total milestones plus tiered royalties up to mid-twenties percent on U.S./Canada sales; cash runway extended into 2028.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) at the November 28 PDUFA date, delaying or denying approval.
- Commercial execution risk: Azurity's launch and sales ramp may underperform expectations.
- Dilution risk: despite the $30M upfront, the company may still need additional capital if milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088040 |
| Document: ea0301528-6k_poly.htm | 0001213900-26-088040 |
| Document: 0001213900-26-088040-index-headers.html | 0001213900-26-088040 |
| Document: 0001213900-26-088040-index.html | 0001213900-26-088040 |
| Document: 0001213900-26-088040.txt | 0001213900-26-088040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 13w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers